REVIEW ARTICLE

Management of Exercise-Induced Bronchospasm in Children

Leslie Hendeles, PharmD,^{1,2} Michael J. Asmus, PharmD,¹ and Sarah Chesrown, MD, PhD²

¹Department of Pharmacy Practice, College of Pharmacy and the ²Department of Pediatrics, Pulmonary Division, College of Medicine, University of Florida, Gainesville, Florida

Bronchospasm precipitated by exercise is often indistinguishable from bronchospasm produced by other stimuli. Symptoms result from airflow limitation and include wheezing, cough, chest tightness, dyspnea and sometimes hypoxemia. The prevalence of exercise-induced bronchospasm varies from 30%-90%, but virtually all patients with current asthma will experience a decrease in lung function if the exercise is sufficiently vigorous, especially in cold, dry environmental conditions. Exercise-induced bronchospasm is more prevalent in children than in adults, probably because children are physically more active. It is also more prevalent among elite winter sports athletes. The pathogenesis of exercise-induced bronchospasm involves a defect in respiratory heat exchange that probably triggers mast cell and eosinophil release of bronchoconstricting mediators. The goal of therapy is prevention of symptoms. This may be accomplished by pre-treating patients with isolated exercise-induced bronchospasm using an inhaled rapid-onset β_2 -adrenergic agonist before a scheduled activity or by treating the underlying inflammation when exercise-induced bronchospasm is part of the clinical syndrome of persistent asthma. In the later instance, either an inhaled corticosteroid, an oral leukotriene modifier, or a combination of both, depending on severity, may be required to prevent exercise-induced bronchospasm associated with activities of daily living. In addition, some of these patients may still require pre-treatment with a short-acting inhaled β_2 -agonist before a scheduled vigorous activity, especially in very cold ambient temperatures. Because the duration of bronchoprotection decreases with daily use (tachyphylaxis), long acting β_2 -adrenergic agonists (e.g., formoterol, salmeterol) have a limited role in treating exercise-induced bronchospasm.

Keywords: exercise-induced bronchospasm, pediatrics

J Pediatr Pharmacol Ther 2003;8:13-21

INTRODUCTION

Exercise-induced bronchospasm, exercise-induced asthma, and thermally-induced asthma are synonymous terms describing acute airway narrowing that develops immediately after vigorous physical activity in patients with asthma. Although estimates of the prevalence of this condition have varied from 30-90%,¹ virtually all patients with current asthma will experience a decrease in lung function if the exercise is intense enough,² especially in very cold, dry environmental conditions. It may be more prevalent in children than in adults, probably because chil-

dren are physically more active. Also, the prevalence is higher in elite winter sport athletes than in summer Olympic participants.³ Exercise-induced bronchospasm may be just one of the many triggers in persistent asthma or may be the primary clinical manifestation in patients with mild intermittent disease (i.e., "isolated exercise-induced bronchospasm"). Often patients with isolated exercise-induced bronchospasm also report asthma symptoms in association with viral upper respiratory tract infections, but are free of symptoms for extended periods in the absence of these triggers.

PATHOPHYSIOLOGY

Strenuous exercise is a potent, naturally occurring provocation of airway narrowing in patients with asthma, but does not elicit broncho-

Address correspondence to: Leslie Hendeles, PharmD, University of Florida Health Sciences Center (Box 100486), Gainesville, FL 32610-0486 email: hendeles@cop.ufl.edu
© Pediatric Pharmacy Advocacy Group, Inc.

Figure 1. Schematic representation of the change in forced expiratory volume in the first second (FEV1) typically seen immediately, and for the first 75 min after exercise in an individual with exercise-induced bronchospasm. FEV1 reaches a nadir within 5-10 min after exercise and spontaneously recovers to within 5% of the pre-exercise value by about 60 min. Adapted from Leff et al.⁴

spasm in those who do not have the disease. The typical pattern of response during exercise is initial bronchodilation that disappears when exercise stops. Airway narrowing begins almost immediately thereafter. The decrease in lung function reaches a peak in 5-10 minutes and then spontaneously remits completely within 75 minutes (Figure 1).⁴ A positive exercise-induced bronchospasm response is defined as a $\geq 15\%$ reduction in the forced expired volume in the first second (FEV1) of a forced vital capacity maneuver.⁵

The pathogenesis of exercise-induced bronchospasm continues to be debated among pulmonary physiologists. Despite the controversy, the general pathology behind exercise-induced bronchospasm involves a defect in respiratory heat exchange that probably triggers mast cell and eosinophil release of bronchoconstricting mediators (Figure 2).⁶ The severity of airway narrowing that occurs following exercise is a function of the absolute quantity of air exchanged per minute (minute ventilation), the temperature of inhaled air, and the water content of the inspired gas.⁷ For a given set of inspired air conditions, a higher minute ventilation results in greater airway narrowing. Thus, strenuous exertion such as running or pedaling a bicycle uphill, evokes a greater response than does walking or pedaling a bicycle over level ground. For a given level of minute ventilation, cooling and drying the inspired air exacerbates the exercise-induced bronchospasm. Importantly, inhaling air that is conditioned to match body tempera-

ture and humidity totally prevents exercise-induced bronchospasm.⁸ It is now generally accepted that the pathogenesis of exercise-induced airway obstruction is closely associated with the conditioning of inspired air.⁹ The purpose of this conditioning process is to heat and humidify the inspired air so that by the time it reaches the alveoli, it is fully saturated with water vapor at body temperature. The net effect of these thermal exchanges on inspiration is to cool the airway mucosa. Then, as warm humidified air is exhaled, recovery of both heat and water occurs, from the air to the mucosa. As the airways are not perfect heat exchangers, only about one third of the heat transferred to the air during inspiration is reclaimed during expiration. However, experimental evidence indicates that airway cooling alone is only one variable and must be followed by rapid airway rewarming for bronchoconstriction to occur.⁹ In fact, exercise-induced bronchospasm is more intense when subjects breathe warm humidified air immediately after exercise.¹⁰

Many investigators argue that mediators released from mast cells and eosinophils in the airways play an important role in the pathogenesis of exercise-induced bronchospasm.⁶ However, the results of experiments designed to document this association have been inconsistent, and the issue remains controversial. Studies searching for various inflammatory mediators in blood,

Figure 2. Schematic representation of the proposed pathogenesis of exercise-induced bronchospasm. Development of exercise-induced bronchospasm involves a defect in respiratory heat exchange that probably triggers mast cell and eosinophil release of bronchoconstricting mediators.

urine and bronchoalveolar lavage fluid before and after exercise have produced conflicting results.^{11,12} Drugs with activity against inflammatory cells (e.g., inhaled corticosteroids)^{13,14} or their secretory products (e.g., leukotriene modifiers)^{4,15} are often effective in attenuating exercise-induced bronchospasm. Since urinary excretion of leukotriene E₄ is increased during exercise-induced bronchospasm¹⁶ and leukotriene biosynthesis inhibitors¹⁷ and receptor antagonists attenuate exercise-induced bronchospasm,^{4,15,16,18-20} it is likely that release of these mediators of inflammation plays an important but not exclusive role in the pathogenesis of exercise-induced bronchospasm. In contrast, cetirizine,²¹ a potent H1-receptor antagonist, and high doses of loratidine²² do not attenuate exercise-induced bronchospasm even though human lung mast cells release histamine *in vitro*. These data suggest that hista-

mine is not released in sufficient quantities *in vivo* to play an important role in exercise-induced bronchospasm. Lastly, McFadden²³ has hypothesized that rapid expansion of blood volume in peribronchial vasculature plexi may be an important cause of airway narrowing during exercise-induced bronchospasm, but so far this hypothesis has not been tested.

CLINICAL FEATURES

Asthma attacks precipitated by vigorous exercise are indistinguishable from symptoms produced by other stimuli. They include wheezing, cough, chest tightness and dyspnea in association with airflow limitation and sometimes hypoxemia. For symptoms to occur, exertion needs to be both vigorous and sustained. During exercise the airways actually dilate and only after the

TABLE. Medications documented to attenuate exercise-induced bronchospasm

Drug	Dosage Form	Dose	Relative Efficacy *				Reference
			Single Dose		Multiple Doses		
			Intensity †	Duration	Intensity †	Duration	
β2-adrenergic agonist							
Albuterol	MDI, DPI	200–400 µg	++++	1-2 h	paradoxical worsening	0	29, 40, 41
Formoterol	DPI	9–12 µg	++++	8 h		unknown	unknown
Salmeterol	MDI, DPI	42–50 µg	++++	9 h	++++	<4	18, 19, 33–36
Corticosteroids							
Budesonide	MDI	400 µg/d	Not effective	0	++++	≥12	13
Fluticasone	MDI	200 µg/d	Not effective	0	++++	≥12	14
Mast-Cell Stabilizers							
Cromolyn	Nebulizer	20 mg	+++	2 h	+++	2	43
	MDI	2 mg	++	2 h	++	2	43, 44
Leukotriene Modifiers							
Montelukast	PO	5 mg	++	20 h	++	20 h	4, 18–20
Zafirlukast	PO-fasting	10 mg	++	12 h	++	12 h	15
Theophylline							
Rapid Release	PO	At serum concentration >10 µg/mL	+++	<6 h	+++	<6h	45, 46

*= There are few comparative studies and none comparing all classes of drugs. These are the author's estimates of relative efficacy based on an aggregate of published reports; †= Attenuation compared to placebo (% protection); ++++ = ≥90%; ++ = 50%

Figure 3. Mean percent protection from exercise-induced bronchospasm in 197 subjects (age 14–45 yr). Subjects were randomized to receive montelukast 10 mg once daily (●) or inhaled salmeterol 50 µg twice daily (□) in a double blind, double-dummy, parallel group designed study. Standardized exercise challenges were performed at the trough of each regimen in the late afternoon 9 h after salmeterol and 21 h after the last dose of montelukast. Percent protection was calculated from the area under the post-exercise FEV1-time curve. Treatment with montelukast and salmeterol were equivalent at day 3. At weeks 4 and 8, however, salmeterol treated subjects had significantly less bronchoprotection against exercise (i.e., tachyphylaxis) compared to treatment with montelukast. Adapted from Villaran et al.¹⁹ The † symbol indicates $P < 0.002$.

work is stopped, do airflow limitation and symptoms develop. The inability to complete a given activity because of tachypnea and dyspnea is usually caused by a lack of fitness or pre-existing airflow limitation and not exercise-induced bronchospasm. This time course of symptom appearance is important in the diagnosis of exercise-induced bronchospasm. For example, shortness of breath that develops during exercise but improves afterwards, should raise the specter of an alternative diagnosis. Subsequent to a single exercise period, there is a refractory period of about an hour or less during which the same level of activity does not produce exercise-induced bronchospasm. This may result from mast cell release of prostaglandins (e.g., PGE_2) that inhibit exercise-induced bronchospasm.²⁴

The intensity of airway responsiveness to exercise is affected by the underlying state of airway reactivity, and the temperature and humidity of ambient air. However, it can't be predicted by the baseline FEV1.²⁵ The intensity of bronchospasm required to produce symptoms varies between patients, as well as within the same patient. Airway inflammation and exposure to allergens²⁶ or viral respiratory infections²⁷ increase airway responsiveness to exercise. For example, in a patient with persistent asthma, the magnitude of the post-exercise decrease in FEV1 strongly correlates with the provocative concen-

tration of histamine required to produce a 20% decrease in FEV1 (PC_{20}).²⁸ Consequently, a standardized exercise challenge can be used in place of histamine or a methacholine challenge as a diagnostic test for asthma, to measure airway responsiveness and the long-term effects of medications such as inhaled corticosteroids.⁵

DIAGNOSIS

The initial diagnosis of exercise-induced bronchospasm is based upon clinical history and is confirmed by response to therapy. A 200–400 µg dose of albuterol (i.e., 2–4 actuations), delivered by metered-dose inhaler or dry powder inhaler 15 minutes before an activity, should completely prevent symptoms.²⁹ If this does not occur, the clinician should refer the patient to an asthma specialist who can perform a standardized exercise challenge test and consider alternative diagnoses such as vocal cord dysfunction or exercise-induced hyperventilation,³⁰ which can masquerade as exercise-induced bronchospasm. A $\geq 15\%$ decrease in FEV1 after a standardized 6-minute period of exercise at $>80\%$ of maximum aerobic capacity confirms the diagnosis of exercise-induced bronchospasm.⁵ In patients with a high level of fitness or elite athletes, a higher level of workload, a longer duration of exercise or breathing cold dry air during the chal-

lenge, may be required to induce bronchospasm.³

MANAGEMENT

The management of exercise-induced bronchospasm in children depends upon the clinical pattern of asthma in the individual patient and the activities that induce symptoms. The principle aim is to prevent exercise-induced bronchospasm so that the patient can participate in whatever activities they choose, including competitive sports. Both warm-ups before and cool-downs (e.g., a slow decrease in activity rather than abrupt cessation) after a scheduled activity that induces symptoms should be recommended.³¹ Since this may not be sufficient and isn't practical for increases in activity that are part of daily living, such as running up stairs to get to class on time, pharmacologic prophylaxis is generally required (Table). Some clinicians encourage their patients to exercise indoors when temperatures outside are near freezing or lower unless they are participating in team sports. Such a recommendation would prevent a child from enjoying ice skating or cross-country skiing. Although we have no experience with this in Florida, it seems to us that pharmacologic therapy should be tried before recommending such a limitation.

EXERCISE-INDUCED BRONCHOSPASM ASSOCIATED WITH PERSISTENT ASTHMA

When exercise-induced bronchospasm is part of persistent asthma, therapy must first be directed toward reducing the underlying airway inflammation with daily maintenance medication. In mild persistent asthma, an inhaled corticosteroid or a leukotriene receptor antagonist such as montelukast^{4,20} (Singulair, Merck & Co., Whitehouse Station, NJ) or zafirlukast¹⁵ taken fasting (Accolate, AstraZeneca, Wilmington, DE) may be sufficient. In patients with very mild disease, there is no evidence that inhaled corticosteroids offer an advantage over leukotriene modifiers which are more convenient and patients take more consistently.³² We prefer montelukast because food does not affect absorption, it is dosed once a day, it does not elevate liver enzymes and has no clinically important drug-drug interactions. However, in children with moderate persistent asthma, one of the more

potent inhaled corticosteroids such as budesonide¹³ (Pulmicort, AstraZeneca, Wilmington, DE) or fluticasone¹⁴ (Flovent, GlaxoSmithKline, Research Triangle Park, NC), delivered by an age-appropriate method, is usually required. Older, less potent, inhaled corticosteroids (e.g. triamcinolone, flunisolide) might be effective, but their effects on exercise-induced bronchospasm have not been studied. In addition, they are less convenient because they require more actuations per day than the newer, more potent agents.

It is common for short-acting β_2 -adrenergic agonists to be prescribed before exercise in all children regardless of their asthma phenotype. However, regular twice-daily use of inhaled corticosteroids markedly attenuates airway responsiveness to standardized exercise challenge in a dose-dependent manner.¹³ With both budesonide¹³ and fluticasone¹⁴, the post-exercise decrease in FEV1 in laboratory conditions averaged <10%. In patients using these drugs in an effective and adherent manner, pre-treatment with a β_2 -agonist is not routinely indicated. If, however, a particular vigorous activity produces exercise-induced bronchospasm in such patients, pre-treatment with an inhaled β_2 -adrenergic agonist is appropriate. This may be especially important when the activity is performed in freezing or subfreezing ambient conditions (e.g. cross-country skiing).

On the other hand, if exercise-induced bronchospasm develops spontaneously during unscheduled activities in a patient taking an inhaled corticosteroid, the clinician first should evaluate inhaler technique and adherence before adding a second controller medication. If an inhaled corticosteroid is being effectively and consistently delivered at an appropriate dose, and exercise-induced bronchospasm associated with activities of daily living persist, a second controller medication is indicated. In this circumstance it is more rational to add a leukotriene modifier rather than a long-acting inhaled β_2 -adrenergic agonist such as formoterol (Foradil, Novartis, East Hanover, NJ) or salmeterol (Serevent, GlaxoSmithKline, Research Triangle Park, NC). This is because the pathogenesis of exercise-induced bronchospasm involves increased production of cysteinyl leukotrienes¹⁶ and a leukotriene modifier provides sustained bronchoprotection.^{15,20} The duration of protection against exercise-induced

bronchospasm (bronchoprotective effect) diminishes with regular use of inhaled salmeterol^{18,19,33-36} (and presumably with formoterol as well) but not with a leukotriene modifier^{4,18,19} (Figure 3). The decrease in duration of protection of long-acting β -agonists with daily use is particularly relevant to children. A dose administered at home before school may not provide protection four or more hours later. In contrast, whatever benefit is derived from a leukotriene modifier will be sustained for the entire dosing interval (Table). With montelukast, a bedtime dose provides protection throughout the next day.²⁰ There is no evidence that a combination of a long-acting β 2-adrenergic agonist and an inhaled corticosteroid (e.g., Advair, Symbicort) provides greater protection from exercise-induced bronchospasm than corticosteroid alone.

The International Olympics Committee has approved the use of all of the above medications (i.e. inhaled corticosteroids, inhaled short-acting and long acting β 2-adrenergic agonists, and oral leukotriene modifiers) for use during competition, but banned the use of oral β -adrenergic agonists,³⁷ because they can modestly increase muscle strength. There are no controlled studies on the efficacy of these drugs in elite winter sport athletes where the prevalence of exercise-induced bronchospasm is increased.³ However, survey results indicate that appropriate use of these medications allow elite athletes to train and compete; several won medals at the 1998 Nagano Winter Olympics.³

ISOLATED EXERCISE-INDUCED BRONCHOSPASM

In patients who experience exercise-induced bronchospasm only in association with scheduled vigorous activity such as jogging several times a week, maintenance medication is not indicated. Rather, in such patients pre-treatment with 200-400 μ g of inhaled albuterol 15 minutes before the activity, using optimal inhalation technique, will block exercise-induced bronchospasm in most patients.²⁹ Salmeterol or formoterol can be used in place of albuterol if the duration of protection from albuterol is insufficient. Because formoterol has a more rapid onset of action, a patient would only have to wait 15 minutes after taking a dose before beginning exercise compared to 30-60 minutes after salmeterol. If pre-

treatment with a β 2-adrenergic agonist is insufficient in patients participating in activities that produce high minute ventilation, especially in cold weather or in elite athletes, a leukotriene modifier can be added one hour or more before the activity.

Exercise-induced bronchospasm that develops from unscheduled activities of daily living can be effectively attenuated by leukotriene modifiers^{15,20} or twice-daily, inhaled corticosteroids.^{13,14} It is possible that once-daily inhaled corticosteroids also may be effective but controlled clinical trials have only examined the effects of twice-daily administration.

Controlled clinical trials in adults have demonstrated that pre-treatment with 2 mg inhaled cromolyn delivered by MDI (Intal, Aventis, Bridgewater, NJ),³⁸ or oral β 2-adrenergic agonists²⁹ (i.e., albuterol) have minimal bronchoprotective effects. Pre-treatment with inhaled ipratropium³⁸ (Atrovent, Boehringer Ingelheim, Ridgefield, CT), oral ketotifen³⁹ (a relatively H1 selective histamine antagonist and mast cell stabilizer, not available in the United States), and most antihistamines^{21,22} are ineffective in preventing exercise-induced bronchospasm. Also, it is noteworthy that maintenance therapy with inhaled albuterol, 2 puffs four times a day for only one week, paradoxically increased exercise-induced bronchospasm and decreased the post-exercise bronchodilator response to albuterol in a double-blind, placebo-controlled crossover study in adults with asthma.⁴⁰

SUMMARY

Exercise frequently triggers symptoms of asthma in children that may cause them to abstain from certain activities. The pathogenesis involves a defect in respiratory heat exchange that probably triggers mast cell and eosinophil release of mediators, including leukotrienes. The goal for therapy is prevention of exercise-induced bronchospasm either by pre-treating the patient with isolated exercise-induced bronchospasm using an inhaled β 2-adrenergic agonist before a scheduled event or treating the underlying inflammation when exercise-induced bronchospasm is part of persistent asthma. Depending upon severity, either an inhaled corticosteroid, an oral leukotriene modifier, or a combination of both may be required to prevent exercise-in-

duced bronchospasm. In some patients, pre-treatment with a short-acting inhaled β_2 -selective agonist may still be required before a particularly vigorous activity, especially in cold, dry environmental conditions. Because of tachyphylaxis, long acting β_2 -adrenergic agonists have a limited role in treating exercise-induced bronchospasm.

ACKNOWLEDGEMENTS: Presented at the International Leukotriene Symposium, Banyu Pharmaceuticals, Tokyo, Japan, June 2001. Drs. Hendeles and Chesrown are conducting clinical studies sponsored by GlaxoSmithKline, Merck, and 3M. Dr. Hendeles has given lectures sponsored by AstraZeneca, GlaxoSmithKline, Merck, and Novartis.

REFERENCES

1. Sano F, Sole D, Nasipitz CK. Prevalence and characteristics of exercise-induced asthma in children. *Pediatr Allergy Immunol* 1998;9:181–5.
2. McFadden ER. Exercise performance in the asthmatic. *Am Rev Respir Dis* 1984;129:S84–7.
3. Wilber RL, Rundell KW, Szmedra L, Jenkinson DM, Im J, Drake SD. Incidence of exercise-induced bronchospasm in Olympic winter sport athletes. *Med Sci Sports Exerc* 2000;32:732–7.
4. Leff JA, Busse WW, Pearlman D, Bronsky EA, Kemp J, Hendeles L, Dockhorn R, Kundu S, Zhang J, Seidenberg BC, Reiss TF. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. *N Engl J Med* 1998;339:147–52.
5. American Thoracic Society. Guidelines for methacholine and exercise challenge testing-1999. *Am J Respir Crit Care Med* 2000;161:309–29.
6. Anderson SD, Brannan JD. Exercise-induced asthma: is there still a case for histamine? (editorial) *J Allergy Clin Immunol* 2002;109:771–3.
7. Deal EC, McFadden ER, Ingram RH, Jaeger JJ. Role of respiratory heat exchange in asthma. *J Appl Physiol* 1984;57:608–9.
8. McFadden ER, Lenner KA, Strohl KP. Postexertional airway rewarming and thermally induced asthma. New insights into pathophysiology and possible pathogenesis. *J Clin Invest* 1986;78:18–25.
9. Gilbert IA, McFadden ER. Airway cooling and rewarming. The second reaction sequence in exercise-induced asthma. *J Clin Invest* 1992;90:699–704.
10. Zawadski DK, Lenner KA, McFadden ER. Comparison of intra-airway temperatures in normal and asthmatic subjects after hyperpnea with hot, cold, and ambient air. *Am Rev Respir Dis* 1988;138:1553–8.
11. Deal EC, Wasserman SI, Soter NA, Ingram RH, McFadden ER. Evaluation of role played by mediators of immediate hypersensitivity in exercise-induced asthma. *J Clin Invest* 1980;65:659–65.
12. Morgan DJ, Phillips MJ, Moodley I, Elliott EV, Davies RJ. Histamine, neutrophil chemotactic factor and circulating basophil levels following exercise in asthmatic and control subjects. *Clin Allergy* 1982;12(suppl):29–37.
13. Pedersen S, Hansen OR. Budesonide treatment of moderate and severe asthma in children: a dose-response study. *J Allergy Clin Immunol* 1995;95:29–33.
14. Hofstra WB, Neijens HJ, Duiverman EJ, Kouwenberg JM, Mulder PG, Kueth MC, Sterk PJ. Dose-response over time to inhaled fluticasone propionate treatment of exercise and methacholine induced bronchoconstriction in children with asthma. *Pediatr Pulmonol* 2000;29:415–23.
15. Pearlman DS, Ostrom NK, Bronsky EA, Bonuccelli CM, Hanby LA. The leukotriene D_4 -receptor antagonist zafirlukast attenuates exercise-induced bronchoconstriction in children. *J Pediatr* 1999;134:273–9.
16. Reiss TF, Hill JB, Harman E, Zhang J, Tanaka WK, Bronsky E, Guerreiro D, Hendeles L. Increased urinary excretion of LTE_4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. *Thorax* 1997;52:1030–5.
17. Meltzer SS, Rechsteiner EA, Johns MA, Cohn J, Blecker ER. Inhibition of exercise-induced asthma by zileuton, a 5-lipoxygenase inhibitor (abstract). *Am J Respir Crit Care Med* 1994;149:A215.
18. Edelman JM, Turpin JA, Bronsky EA, Grossman J, Kemp JP, Ghannam AF, DeLucca PT, Gormley GJ, Pearlman DS. Oral

- montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group. *Ann Intern Med* 2000;132:97–104.
19. Villaran C, O'Neill SJ, Helbling A, van Noord JA, Lee TH, Chuchalin AG, et al. Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast/Salmeterol Exercise Study Group. *J Allergy Clin Immunol* 1999;104:547–53.
 20. Kemp JP, Dockhorn RJ, Shapiro GG, Nguyen HH, Reiss TF, Seidenberg BC, Knorr B. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. *J Pediatr* 1998;133:424–8.
 21. Gong H, Tashkin DP, Dauphinee B, Djahed B, Wu TC. Effects of oral cetirizine, a selective H₁ antagonist, on allergen- and exercise-induced bronchoconstriction in subjects with asthma. *J Allergy Clin Immunol* 1990;85:632–41.
 22. Dahlén B, Roquet A, Inman MD, Karlsson Ö, Naya I, Anstrén G, O'Byrne PM, Dahlén S-E. Influence of zafirlukast and loratadine on exercise-induced bronchoconstriction. *J Allergy Clin Immunol* 2002;109:789–93.
 23. McFadden ER. Hypothesis: exercise-induced asthma as a vascular phenomenon. *Lancet* 1990;335:880–3.
 24. O'Byrne PM. Exercise-induced bronchoconstriction: elucidating the roles of leukotrienes and prostaglandins. *Pharmacotherapy* 1997;17(suppl):31–8.
 25. Killian KJ, Summers E, Watson RM, O'Byrne PM, Jones NL, Campbell EJ. Factors contributing to dyspnea during bronchoconstriction and exercise in asthmatic subjects. *Eur Respir J* 1993;6:1004–10.
 26. Benckhuijsen J, van den Bos JW, van Velzen E, de Bruijn R, Aalbers R. Differences in the effect of allergen avoidance on bronchial hyperresponsiveness as measured by methacholine, adenosine 5'-monophosphate, and exercise in asthmatic children. *Pediatr Pulmonol* 1996;22:147–53.
 27. Glezen WP. Reactive airway disorders in children. Role of respiratory virus infections. *Clin Chest Med* 1984;5:635–43.
 28. Cockcroft DW, Killian DN, Mellon JJ, Hargreave FE. Bronchial reactivity to inhaled histamine: a method and clinical survey. *Clin Allergy* 1977;7:235–43.
 29. Anderson SD, Seale JP, Rozea P, Bandler L, Theobald G, Lindsay DA. Inhaled and oral salbutamol in exercise-induced asthma. *Am Rev Resp Dis* 1976;114:493–500.
 30. Hammo AH, Weinberger MM. Exercise-induced hyperventilation: a pseudoasthma syndrome. *Ann Allergy Asthma Immunol* 1999;82:574–8.
 31. McKenzie DC, McLuckie SL, Stirling DR. The protective effects of continuous and interval exercise in athletes with exercise-induced asthma. *Med Sci Sports Exerc* 1994;26:951–6.
 32. Sherman J, Patel P, Hutson A, Chesrown S, Hendeles L. Adherence to oral montelukast and inhaled fluticasone in children with persistent asthma. *Pharmacotherapy* 2001;21:1464–7.
 33. Simons FE, Gerstner TV, Cheang MS. Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. *Pediatrics* 1997;99:655–9.
 34. Nelson JA, Strauss L, Skowronski M, Ciuffo R, Novak R, McFadden ER. Effect on long-term salmeterol treatment on exercise-induced asthma. *N Engl J Med* 1998;339:141–6.
 35. Ramage L, Lipworth BJ, Ingram CG, Cree IA, Dhillon DP. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. *Resp Med* 1994;88:363–8.
 36. Drotar DE, Davis EE, Cockcroft DW. Tolerance to the bronchoprotective effect of salmeterol 12 hours after starting twice daily treatment. *Ann Allergy Asthma Immunol* 1998;80:31–4.
 37. Nastasi KJ, Heinly TL, Blaiss MS. Exercise-induced asthma and the athlete. *J Asthma* 1995;32:249–57.
 38. Bundgaard A, Rasmussen FV, Madsen L. Pretreatment of exercise-induced asthma in adults with aerosols and pulverized tablets. *Allergy* 1980;35:639–45.
 39. Tanser AR, Elmes J. A controlled trial of ketotifen in exercise-induced asthma. *Br J Dis Chest* 1980;74:398–402.

40. Hancox RJ, Subbarao P, Kamada D, Watson RM, Hargreave FE, Inman MD. β 2-agonist tolerance and exercise-induced bronchospasm. *Am J Respir Crit Care Med* 2002;165:1068–70.
41. Berkowitz R, Schwartz E, Bukstein D, Grunstein M, Chai H. Albuterol protects against exercise-induced asthma longer than metaproterenol sulfate. *Pediatrics* 1986;77:173–8.
42. Boner AL, Spezia E, Piovesan P, Chiocca E, Maiocchi G. Inhaled formoterol in the prevention of exercise-induced bronchoconstriction in asthmatic children. *Am J Respir Crit Care Med* 1994;149:935–9.
43. Patel KR, Wall RT. Dose-duration effect of sodium cromoglycate aerosol in exercise-induced asthma. *Eur J Respir Dis* 1986;69:256–60.
44. Tullett WM, Tan KM, Wall RT, Patel KR. Dose-response effect of sodium cromoglycate pressurised aerosol in exercise induced asthma. *Thorax* 1985;40:41–4.
45. Pollock J, Kiechel F, Cooper D, Weinberger M: Relationship of serum theophylline concentration to inhibition of exercise-induced bronchospasm and comparison with cromolyn. *Pediatrics* 1977;60:840–4.
46. Bierman CW, Shapiro GG, Pierson WE, Dorsett CS: Acute and chronic theophylline therapy in exercise-induced bronchospasm. *Pediatrics* 1977;60:845–9.